Journal
PLOS ONE
Volume 7, Issue 1, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0030174
Keywords
-
Categories
Funding
- United States National Institutes of Health (NIH) [DK070016]
- Nebraska Tobacco Settlement Biomedical Research Program Award [LB-595]
Ask authors/readers for more resources
It is prevailingly thought that the antiestrogens tamoxifen and ICI 182, 780 are competitive antagonists of the estrogenbinding site of the estrogen receptor-alpha (ER-alpha). However, a plethora of evidence demonstrated both antiestrogens exhibit agonist activities in different systems such as activation of the membrane-initiated signaling pathways. The mechanisms by which antiestrogens mediate estrogen-like activities have not been fully established. Previously, a variant of ER-a, EP-a36, has been cloned and showed to mediate membrane-initiated estrogen and antiestrogen signaling in cells only expressing ER-a36. Here, we investigated the molecular mechanisms underlying the antiestrogen signaling in ERnegative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of endogenous ER-alpha 36. We found that the effects of both 4-hydoxytamoxifen (4-OHT) and ICI 182, 780 (ICI) exhibited a non-monotonic, or biphasic dose response curve; antiestrogens at low concentrations, elicited a mitogenic signaling pathway to stimulate cell proliferation while at high concentrations, antiestrogens inhibited cell growth. Antiestrogens at l nM induced the phosphorylation of the Src-Y416 residue, an event to activate Src, while at 5 mM induced Src-Y527 phosphorylation that inactivates Src. Antiestrogens at 1 nM also induced phosphorylation of the MAPK/ERK and activated the Cyclin D1 promoter activity through the Src/EGFR/ STAT5 pathways but not at 5 mu M. Knock-down of ER-alpha 36 abrogated the biphasic antiestrogen signaling in these cells. Our results thus indicated that ER-alpha 36 mediates biphasic antiestrogen signaling in the ER-negative breast cancer cells and Src functions as a switch of antiestrogen signaling dependent on concentrations of antiestrogens through the EGFR/STAT5 pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available